Tianyin Pharmaceutical Co., Inc. Receives Chinese SFDA New Product Approvals for 2 Generic Products
December 01 2009 - 7:00AM
PR Newswire (US)
Pediatric Fever and Cough Oral Liquid Address Large Market
Antibacterial and Anti-inflammatory Capsules to Be Manufactured in
Company's New Facility CHENGDU, China, Dec. 1
/PRNewswire-Asia-FirstCall/ -- Tianyin Pharmaceutical Co., Inc.,
(NYSE Amex: TPI), a manufacturer and supplier of modernized
traditional Chinese medicine ("TCM") based in Chengdu, China, today
announced that it has received approvals from the Chinese State
Food and Drug Administration (SFDA) to produce Pediatric Fever and
Cough Oral Liquid in dosage form of 10 ml/tube (SFDA approval
number Z20093060) and Antibacterial and Anti-inflammatory Capsules
in dosage form of 0.27 gram/capsule (SFDA approval number
Z20090855). Pediatric Fever and Cough Oral Liquid is a generic
prescription TCM that is used for respiratory tract infections and
influenza of children to effectively reduce symptoms such as fever,
shakes, cough, phlem, shortness of breath, dry mouth and sore
throat. According to Tianyin's market research and estimation,
annual sales of this type of products are approximately $1.1
billion in China. Tianyin expects the demand of this product will
increase during the wintertime flu season and that our introduction
of this product will increase the Company's market share in the
pediatric medicine market. Antibacterial and Anti-inflammatory
Capsules is a generic OTC TCM which is used mainly as natural
antibiotics to treat bacterial infection and inflammation. It has
minimal side effects when compared to western antibiotics. Tianyin
estimates that total annual sales of antibacterial and
anti-inflammatory products are approximately $1.5 billion in China.
Tianyin expects to gain a portion of the market share in
antibiotics medicine through the production and marketing of
Antibacterial and Anti-inflammatory Capsules. The product will be
manufactured in Company's new production facility. "We are very
pleased to receive approvals for our Pediatric Fever and Cough Oral
Liquid and Antibacterial and Anti-inflammatory Capsules from the
Chinese SFDA. One of our key growth strategies is to further expand
our portfolio," Dr. Guoqing Jiang, Chairman and CEO of Tianyin
Pharmaceutical Co., Inc., commented. "These products further
complement our product portfolio and create additional revenue
opportunities for indications which we have not previously
addressed. We will immediately leverage current distribution
network and available production capacity to produce these two
products." About Tianyin Pharmaceuticals Tianyin is a manufacturer
and supplier of modernized Traditional Chinese Medicine ("TCM") in
China. It was established in 1994 and acquired by the current
management team in August 2003. It has a comprehensive product
portfolio of 39 products, 22 of which are listed in the highly
selective National Medicine Catalog of the National Medical
Insurance program. Tianyin owns and operates two GMP manufacturing
facilities and an R&D platform supported by leading Chinese
academic institutions. The Company has a pipeline of 17
pharmaceutical products pending approval. Tianyin has an extensive
nationwide distribution network throughout China with a sales force
of 720 salespeople. Tianyin is headquartered in Chengdu, Sichuan
Province with two manufacturing facilities and a total of 1,365
employees. For more information about Tianyin, please visit
http://www.tianyinpharma.com/ . Safe Harbor Statement The
Statements which are not historical facts contained in this press
release are forward-looking statements that involve certain risks
and uncertainties including but not limited to risks associated
with the uncertainty of future financial results, additional
financing requirements, development of new products, government
approval processes, the impact of competitive products or pricing,
technological changes, the effect of economic conditions and other
uncertainties detailed in the Company's filings with the Securities
and Exchange Commission. For more information, please contact: For
the Company: Allen Tang, Ph.D., MBA, Assistant to the CEO Tel:
+86-158-2122-5642 Email: Investors: Mr. Matthew Hayden, HC
International Tel: +1-561-245-5155 Email: Web:
http://www.hcinternational.net/ DATASOURCE: Tianyin Pharmaceutical
Co., Inc. CONTACT: Allen Tang, Ph.D., MBA, Assistant to the CEO of
Tianyin Pharmaceutical Co., Inc., +86-158-2122-5642, ; or
Investors, Matthew Hayden of HC International, +1-561-245-5155, Web
site: http://www.tianyinpharma.com/ http://www.hcinternational.net/
Copyright